To confirm the crucial role of p53 in the ability of GnRH agonists to sensitize prostate cancer cells to the cytotoxic activity of docetaxel, experiments were performed in p53-null PC3 prostate cancer cells [61]. This evidence concerns the gene TP53 and prostate carcinoma.